Current News Natrion receives investment from Illini Angels in the second tranche of Natrion’s $3+ million seed funding round. Posted on December 6, 2023December 6, 2023 by Cort Meyerson 06 Dec Cort Meyerson myNEO Therapeutics and CureVac N.V. announced that CureVac has exercised two exclusive options on selected sets of potential cancer vaccine antigen targets Natrion founders Alex Kosyakov and Thomas Roufflac named in Forbes 30 Under 30 in the Energy category, 2024.